| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
L-Octanoylcarnitine hydrochloride targets the carnitine shuttle system and mitochondrial fatty acid oxidation. As an acylcarnitine, it facilitates the transport of fatty acids into mitochondria for β-oxidation. It may help in enhancing fatty acid utilization and improving mitochondrial function in metabolic disorders. It has been studied in breast cancer research.
|
|---|---|
| ln Vitro |
The rat liver mitochondria (RLM) emit H2O2 when exposed to 0.2 mM of L-octanoylcarnitine hydrochloride [1].
In vitro, L-Octanoylcarnitine hydrochloride is used to study fatty acid metabolism, mitochondrial function, and energy production. It serves as a substrate for enzymes involved in the carnitine shuttle. Its activity is measured by assessing fatty acid oxidation rates, mitochondrial respiration, and acylcarnitine levels in cultured cells. |
| ln Vivo |
In male mice fed a high-fat diet (HFD), L-octanoylcarnitine hydrochloride base lowers respiratory conductance and mucosal and detrusor force-flow respiration [2].
In vivo, L-Octanoylcarnitine hydrochloride is a plasma metabolite and the physiologically active form of octanoyl-DL-carnitine. It is involved in fatty acid metabolism and energy production. It has been explored for potential therapeutic applications in metabolic disorders and breast cancer research. |
| Enzyme Assay |
In vitro enzyme assays with L-Octanoylcarnitine hydrochloride typically involve studying carnitine palmitoyltransferase (CPT) and other enzymes of the carnitine shuttle. The compound is used as a substrate to measure enzyme activity. Standard assays involve incubating with enzyme preparations and measuring products by spectrophotometric or radiometric methods.
|
| Cell Assay |
In vitro cell culture experiments with L-Octanoylcarnitine hydrochloride involve treating various cell types including muscle cells, hepatocytes, and cancer cells. Cells are treated with the compound, and endpoints include assessment of mitochondrial function, fatty acid oxidation, ATP levels, and cell viability. These experiments characterize the metabolic effects of the compound.
|
| Animal Protocol |
In vivo animal experiments with L-Octanoylcarnitine hydrochloride typically involve administering the compound to animal models of metabolic disorders or cancer. Key endpoints include assessment of fatty acid metabolism, mitochondrial function, energy production, and tumor growth. These studies evaluate the therapeutic potential of the compound.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of L-Octanoylcarnitine hydrochloride reflect its role as a carnitine derivative. It is absorbed from the gastrointestinal tract and distributed to tissues. It is metabolized to octanoyl-CoA and carnitine and is excreted in urine. Its plasma half-life is relatively short. It should be stored at appropriate conditions.
|
| Toxicity/Toxicokinetics |
L-Octanoylcarnitine hydrochloride has a low toxicity profile as a naturally occurring metabolite. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have been conducted in the context of its use as a research compound.
|
| References |
|
| Additional Infomation |
L-Octanoylcarnitine hydrochloride is a medium-chain acylcarnitine and the physiologically active form of octanoyl-DL-carnitine. It is a plasma metabolite used in biochemical research to study mitochondrial function, fatty acid metabolism, and energy production. It has been explored for potential therapeutic applications in metabolic disorders and breast cancer research. The compound is not a drug and has no approved therapeutic indications.
|
| Molecular Formula |
C15H30CLNO4
|
|---|---|
| Molecular Weight |
323.856004238129
|
| Exact Mass |
323.186
|
| CAS # |
54377-02-5
|
| Related CAS # |
Octanoylcarnitine chloride;14919-35-8;L-Octanoylcarnitine;25243-95-2;L-Octanoylcarnitine-d3;204259-56-3
|
| PubChem CID |
25105264
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
21
|
| Complexity |
297
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[Cl-].O(C(CCCCCCC)=O)C(CC(=O)O)C[N+](C)(C)C
|
| InChi Key |
MYMFUYYXIJGKKU-BTQNPOSSSA-N
|
| InChi Code |
InChI=1S/C15H29NO4.ClH/c1-5-6-7-8-9-10-15(19)20-13(11-14(17)18)12-16(2,3)4;/h13H,5-12H2,1-4H3;1H/t13-;/m1./s1
|
| Chemical Name |
[(2R)-3-carboxy-2-octanoyloxypropyl]-trimethylazanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (308.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0878 mL | 15.4388 mL | 30.8775 mL | |
| 5 mM | 0.6176 mL | 3.0878 mL | 6.1755 mL | |
| 10 mM | 0.3088 mL | 1.5439 mL | 3.0878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
